Taro Provides Results for September 30, 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Taro Pharma (TARO) Misses Q2 EPS by 36c
October 28, 2021 5:16 PM EDTTaro Pharma (NYSE: TARO) reported Q2 EPS of $0.66, $0.36 worse than the analyst estimate of $1.02. Revenue for the quarter came in at $132 million versus the consensus estimate of $153.23 million.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
... More